NASDAQ
14.74USD
+0.01 (+0.03%)
No scored catalysts in the window yet.
Market cap
1.9B
P/E
—
EPS
—
Beta
-0.28
52W range
6.38-14.76
Day range
14.74–14.75
Open
14.74
Prev close
14.74
Volume
2.8M
Avg volume
2.9M
Dividend
0.00
IPO
2000-10-27
https://www.prnewswire.com/news-releases/bluenergies-announces-closing-of-non-brokered-private-placement-of-units-for-gross-proceeds-of-c20-7-million-302833663.html · 7/23/2026+0.60
https://www.foxbusiness.com/markets/budget-airlines-seek-federal-aid-spirit-shuts-down-after-failed-rescue · 5/4/2026+0.20
https://www.prnewswire.com/news-releases/tap-air-portugal-selects-new-jfk-terminal-6-for-future-operations-302728858.html · 3/30/2026+0.40
https://www.cnbc.com/2026/02/24/spirit-airlines-bankruptcy-flights.html · 2/24/2026+0.00
https://www.newsfilecorp.com/release/265413/Lode-Gold-Closes-1.51-Million-Upsized-Private-Placement · 9/6/2025+0.00
BELLUS Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, and founded in 1993. The firm focuses on developing therapeutic solutions for refractory chronic cough (RCC) and other related cough hypersensitivity conditions. Its leading product candidate, BLU-5937, an antagonist designed to block the P2X3 receptor, is currently progressing through Phase II clinical trials for the treatment of both RCC and chronic pruritus.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
